Sector News

Mallinckrodt buys Ikaria for $2.3bn

March 6, 2015
Life sciences
Dublin, Ireland-based speciality biopharma Mallinckrodt is extending its hospital-based offering with a $2.3-billion purchase of US privately-held critical care group Ikaria.
 
A Mallinckrodt subsidiary will acquire the company from a Madison Dearborn-led investor group, with the transaction is expected to close early in the second quarter assuming closing conditions are satisfied.
 
The firm says the deal will further accelerate growth in its Specialty Brands segment, broaden its hospital presence, and diversify its portfolio with “high-value, high-margin critical care products”.
 
The move is expected to add at least $150 million in net sales and be accretive to Mallinckrodt’s fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.
 
By Selina McKee
 
Source: Pharma Times

1 response to “Mallinckrodt buys Ikaria for $2.3bn

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend